摘要
目的研究盐酸小檗碱对小鼠实验性溃疡性结肠炎的保护作用。方法实验设正常、模型、柳氮磺胺吡啶(SASP,520 mg·kg-1)和盐酸小檗碱(berberine chloride,BER)低、中、高(15 mg·kg-1、45 mg·kg-1、150 mg·kg-1)剂量组。六组小鼠自由饮用4%葡聚糖硫酸钠(dextran sulphate sodium, DSS)水溶液或蒸馏水,同时分别灌胃给予干预药物或溶剂(0·2 mL / 10 gWt,1次/ d×7 d)。以疾病活动指数(Disease activity index, DAI)评价小鼠临床症状。生化方法测定结肠组织MDA含量,SOD、MPO活性;HE染色切片,评估结肠组织病理改变;免疫组化检测ICAM-1、NF-κB p65蛋白表达水平。结果模型组DAI显著增高,结肠黏膜损伤严重;MDA含量、MPO活性及ICAM-1和NF-κB p65表达明显升高,SOD活性下降。SASP 520 mg·kg-1能明显逆转上述情况改变;BER使DAI减小,结肠黏膜损伤减轻, MDA含量、MPO活性降低,阻遏ICAM-1和NF-κB p65蛋白表达,升高SOD活性,且呈现一定剂量依赖性。结论BER可能通过抗氧自由基作用,抑制ICAM-1表达及NF-κB激活,缓解DSS所致的小鼠结肠炎症。
Aim To investigate the effect in berberine chloride （BER） on experimental ulcerative colitis in mice. Methods BALB/C mice in 6 groups were allowed to drink either 4% dextran sulfate sodium （DSS） solution or distilled water freely with different doses of BER （15 mg·kg^-1, 45 mg·kg^-1, 150 mg·kg^-1） or sallcylazosulfapyridine （SASP, 520 mg·kg^-1）, and solvent （0. 2 mL/10 mg Wt） once a day for 7 d, respectively. The symptom of ulcerative colitis was evaluated by disease activity index （DAI）. Myeloperoxidase （MPO） and superoxide dismutase （SOD） activities and malondialdehyde （MDA） content were determined by HE staining and immunohistochemistry of expressions of NF-κB p65 and intercellular adhesion molecule 1 （ ICAM-1 ） proteins to observe the damage to colon tissues and possible mechanisms. Results DAI, MPO activity, MDA content and expressions of ICAM-1 and NF-κB p65 were markedly increased, while SOD activity decreased in DSS-treated mice. Treatment of mice with different doses of BER or SASP significantly decreased DAI, MPO activity and MDA content, improved histological changes of colon tissues, blunted the expressions of NF-κB p65 and ICAM-1 proteins, and enhanced SOD activity. Conclusion Berberine chloride has excellent therapeutic effect on ulcerative colitis caused by DSS in mice. The possible mechanism may be related to its antioxidant and anti-inflammatory activities associated with inhibiting the NF-κB activation and ICAM-1 expression.
基金
AProject of the Health Bureau of Chongqing (No.2004-B-31)
